Serological speciation of human T-cell leukaemia virus infections using synthetic peptide antigens

✍ Scribed by Jennifer H. C. Tosswill; Lindsay McAlpine; Philip P. Mortimer

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 320 KB
• Volume: 40
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890400116

✦ Synopsis

Abstract

In order to assess the specificity and sensitivity of two peptide‐based assays (Synth^TM^ HTLV‐I and HTLV‐II enzyme‐linked immunoassay [EIA] [UBI] and Select‐HTLV^TM^ EIA [IAF]) in discriminating between antibody to HTLV‐I and HTLV‐II infection, a panel of 186 well‐characterised serum/plasma samples was tested by the two assays. The panel comprised 160 samples that by Western blot were confirmed to contain antibodies to HTLV‐I/II and 26 samples that showed reactivity with gag but not env gene products. Both assays were found to be specific in that they did not misclassify any of the 80 specimens from cases of tropical spastic paraparesis or adult T‐cell leukaemia/lymphoma, diseases believed to be HTLV‐I associated, as anti‐HTLV‐II positive. Of the 160 specimens confirmed as anti‐HTLV‐I/II positive by Western blot, 6.2% were negative or untypable in the Synth EIA compared with 13.7% in the Select EIA. Of the 26 Western blot indeterminate samples, 16 were negative by both assays. Five were typed as anti‐HTLV‐I by both assays and 5 as anti HTLV‐II by Select EIA only. The peptide based EIAs offer an economical and, in most cases, reliable means of discriminating between anti‐HTLV‐I and anti‐HTLV‐II. However, they should only be applied to sera that have been confirmed by Western blot or other methods as anti‐HTLV‐I/II positive. Even then they may fail to speciate sera from non‐Japanese, non‐Afrocaribbean populations. © 1993 Wiley‐Liss, Inc.